Please assess the completion status of the following clinical trial:

Trial Title: Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria~1. Age ≥ 18 at time of consent.~2. Ability to provide written informed consent and HIPAA authorization.~3. Pathological diagnosis of squamous cell carcinoma of the lung.~4. Staging PET/CT (invasive mediastinal staging strongly encouraged but not required).~5. Tumors \< 7cm~6. Any location eligible for SBRT (including, but not limited to, peripheral, chest wall abutting and central tumors)~7. N0 M0 disease~8. Plan to undergo four or five fraction SABR~9. Baseline PFTs available within 6 months of treatment start or will be obtained prior to treatment start (no finding will exclude patient from enrollment in trial)~Exclusion Criteria~1. Previous radiation therapy to the lung per investigator discretion.~2. Inability to comply with treatment per investigator discretion.~3. Inability to follow standard of care follow up recommendations per investigator discretion.~4. KPS\<40

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase 1/Dose Level 1 (Type: EXPERIMENTAL): 11 Gy will be given in 5 fractions for a total dose of 55 Gy
- Phase 1/Dose Level 2 (Type: EXPERIMENTAL): 12 Gy will be given in 5 fractions for a total dose of 60 Gy
- Phase 1/Dose Level 3 (Type: EXPERIMENTAL): 13 Gy will be given in 5 fractions for a total dose of 65 Gy
- Phase 1/Dose Level 4 (Type: EXPERIMENTAL): 14 Gy will be given in 5 fractions for a total dose of 70 Gy
- Phase 2 (Type: EXPERIMENTAL): The maximum tolerated radiation dose determined during Phase 1 (i.e. 11, 12, 13, or 14 Gy) will be given in 5 fractions for a total dose of 55, 60, 65, or 70 Gy.

Based on this trial design, predict the completion outcome and termination type (if applicable).